GILD

#86
Gilead Sciences, Inc. - Common Stock
134.4 3 USD
-0.85%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
134.41
134.48
Rango anual
104.46
157.27
Cambio diario
-0.85%
Variación mensual
+5.06%
Variación en los últimos 6 meses
+6.95%
Cambio anual
+20.44%
Cierres anteriores
135.5 8
Open
134.4 8
Mínimo
134.4 1
High
134.4 8
Volumen
640
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 166.9 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Fabricantes de medicamentos — general
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
18.96
Relación precio/flujo de caja
5.88
Dividendos por acción
0.82
Rendimiento por dividendo, %
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

Noticias